Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO) . This happens when… read more.
CSL Vifor announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of… read more.
The HeartMate Touch Communication System monitors patients who have an implantable HeartMate 3 Left Ventricular Assist Device. The HeartMate Touch Communication System works with the HeartMate System Controller…. read more.
To treat depression in heart failure, patients can receive with similar efficacy either behavioral activation psychotherapy or antidepressant drug therapy, researchers report. The findings appeared on Jan.17, 2024… read more.
People who live in neighborhoods with higher levels of poverty and unemployment are less likely to fill their heart-failure drug prescriptions than those living in wealthier areas, a… read more.
A new paper in the journal Function, published by Oxford Univetrsity Press, finds that a widely prescribed drug for treating hypertension, amlodipine, is not dangerous for patients, despite recent concerns… read more.
Forxiga (dapagliflozin) from AstraZeneca. has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with… read more.
Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine recently conducted a large-scale analysis to assess the impact of a newly introduced equation used to evaluate… read more.
A recent publication described the holistic approach to drug therapy in a patient with heart failure – an area where treatment has changed considerably over the past 30… read more.
The management of heart failure treatment is probably best done by a primary care team and pharmacists can play a major role in prescribing, says Paul Forsyth, Lead… read more.
The key challenges in heart failure treatment include reaching the target dose, awareness of drug-specific issues that influence effectiveness and tackling adherence problems, according to Paul Forsyth, Lead… read more.
Current thinking advocates the use of ‘four pillars of heart failure therapy’. Paul Forsyth, Lead Pharmacist, Clinical Cardiology at NHS Greater Glasgow and Clyde, explains how this treatment… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
